X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Pfizer with ADCOCK INGRAM HOLDINGS LTD. - S. Africa - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PFIZER vs ADCOCK INGRAM (S. Africa) - Comparison Results

PFIZER    Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

ADCOCK INGRAM (S. Africa)
   Change

Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 PFIZER   ADCOCK INGRAM
EQUITY SHARE DATA
    PFIZER
Mar-18
ADCOCK INGRAM
Jun-14
PFIZER/
ADCOCK INGRAM
5-Yr Chart
Click to enlarge
High Rs2,365366-   
Low Rs1,625264-   
Sales per share (Unadj.) Rs430.3108.9-  
Earnings per share (Unadj.) Rs78.7-27.4-  
Cash flow per share (Unadj.) Rs93.2-22.7-  
Dividends per share (Unadj.) Rs20.000-  
Dividend yield (eoy) %1.00-  
Book value per share (Unadj.) Rs586.585.5-  
Shares outstanding (eoy) m45.75168.78-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.62.9 160.2%   
Avg P/E ratio x25.3-11.5 -220.8%  
P/CF ratio (eoy) x21.4-13.9 -154.5%  
Price / Book Value ratio x3.43.7 92.3%  
Dividend payout %25.40-   
Avg Mkt Cap Rs m91,27153,186 171.6%   
No. of employees `0002.64.3 61.3%   
Total wages/salary Rs m3,1433,338 94.2%   
Avg. sales/employee Rs Th7,484.84,281.9 174.8%   
Avg. wages/employee Rs Th1,195.0777.6 153.7%   
Avg. net profit/employee Rs Th1,369.1-1,078.9 -126.9%   
INCOME DATA
Net Sales Rs m19,68518,382 107.1%  
Other income Rs m1,143129 887.9%   
Total revenues Rs m20,82818,511 112.5%   
Gross profit Rs m5,003-3,185 -157.1%  
Depreciation Rs m663793 83.5%   
Interest Rs m4498 0.8%   
Profit before tax Rs m5,479-4,348 -126.0%   
Minority Interest Rs m0-12 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,878272 691.4%   
Profit after tax Rs m3,601-4,632 -77.7%  
Gross profit margin %25.4-17.3 -146.7%  
Effective tax rate %34.3-6.2 -548.7%   
Net profit margin %18.3-25.2 -72.6%  
BALANCE SHEET DATA
Current assets Rs m24,16713,463 179.5%   
Current liabilities Rs m9,5447,575 126.0%   
Net working cap to sales %74.332.0 231.9%  
Current ratio x2.51.8 142.5%  
Inventory Days Days55111 49.7%  
Debtors Days Days29124 23.2%  
Net fixed assets Rs m9,5147,848 121.2%   
Share capital Rs m45885 536.1%   
"Free" reserves Rs m26,3750-   
Net worth Rs m26,83214,428 186.0%   
Long term debt Rs m255,070 0.5%   
Total assets Rs m36,90027,255 135.4%  
Interest coverage x1,305.5-7.7 -16,884.4%   
Debt to equity ratio x00.4 0.3%  
Sales to assets ratio x0.50.7 79.1%   
Return on assets %9.8-15.2 -64.4%  
Return on equity %13.4-32.1 -41.8%  
Return on capital %20.4-19.8 -103.1%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m-1,4660-   
CASH FLOW
From Operations Rs m3,3181,569 211.5%  
From Investments Rs m-2,383-482 494.6%  
From Financial Activity Rs m-1,1044,602 -24.0%  
Net Cashflow Rs m-1695,689 -3.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ADCOCK INGRAM (S. Africa) is South Africa Rand. All data has been converted at 5.05 Rs / ZAR

Compare PFIZER With: ACTAVIS (US)  MYLAN (US)  TEVA PHARMA (Israel)  

Compare PFIZER With: J.B.CHEMICALS  ELDER PHARMA  AUROBINDO PHARMA  GSK PHARMA  NOVARTIS  



Today's Market

Macroeconomic Cues Guide the Markets This Week(Podcast)

Global markets remained in pressure this week. Pound fell sharply as risk of chaotic Brexit rose.

Related Views On News

PFIZER Announces Quarterly Results (2QFY19); Net Profit Down 13.8% (Quarterly Result Update)

Nov 15, 2018 | Updated on Nov 15, 2018

For the quarter ended September 2018, PFIZER has posted a net profit of Rs 958 m (down 13.8% YoY). Sales on the other hand came in at Rs 5 bn (down 9.0% YoY). Read on for a complete analysis of PFIZER's quarterly results.

PFIZER Announces Quarterly Results (1QFY19); Net Profit Up 60.6% (Quarterly Result Update)

Aug 3, 2018 | Updated on Aug 3, 2018

For the quarter ended June 2018, PFIZER has posted a net profit of Rs 918 m (up 60.6% YoY). Sales on the other hand came in at Rs 5 bn (up 18.4% YoY). Read on for a complete analysis of PFIZER's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)

Nov 6, 2018

If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.

This Was a Large Cap. But Was It Safe?(Chart Of The Day)

Nov 9, 2018

Investing in large caps is not always safe. Consider the right metrics to judge the safety and quality of large caps.

Why the Realty Sector's Recovery Has Been Delayed(Sector Info)

Nov 15, 2018

NBFC and IL&FS crisis have worsened the realty sector woes. Is there a light at the end of the tunnel for real estate sector?

Does it Make Sense to Invest in Offshore Funds?(Outside View)

Nov 6, 2018

Many investors prefer to invest in offshore funds because of the rupee depreciation and on-going downtrend in the markets, but it is to be invested only when there is no option available to invest in India.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PFIZER SHARE PRICE


Nov 16, 2018 (Close)

TRACK PFIZER

PFIZER - ALKEM LABORATORIES COMPARISON

COMPARE PFIZER WITH

MARKET STATS